Illumina completed the acquisition of SomaLogic and related assets from Standard BioTools for $350 million in cash, gaining a CLIA/CAP lab in Boulder and access to SomaScan proteomics capabilities. The deal folds proteomic aptamer technology into Illumina’s NGS ecosystem and was positioned as a strategic move to broaden multi‑omics offerings. Company statements indicate Illumina will leverage existing sequencing, DRAGEN software and Protein Prep assay development to scale protein measurement alongside genomic readouts. The acquisition includes performance milestones and a multi‑year services agreement with the seller, and Illumina said it will maintain Boulder operations for now.